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The B-cell lymphoma-2 (Bcl-2) family of proteins regulates the intrinsic, or mitochondrial pathway of
apoptosis, the ﬁnal common mechanism of cell death in response to a variety of physiologic and
pharmacologic signals, and plays a central role in AML pathogenesis, prognosis and responsiveness to
chemotherapy. Traditionally thought to be an important survival factor for multiple myeloma cells, the
anti-apoptotic Bcl-2 family protein myeloid cell leukemia-1 (Mcl-1) has recently been shown in
preclinical studies to be critical to the development and maintenance of AML, making it an attractive
therapeutic target in this disease. Several characteristics, such as its very short half-life, distinguish
Mcl-1 from other anti-apoptotic Bcl-2 family members. Additionally, Mcl-1 levels are regulated by a
large number of pathways affecting its transcription, translation and degradation. A variety of
approaches exploiting these features have been developed to inhibit directly or indirectly the anti-
apoptotic function of Mcl-1. Many of these lend themselves well to combination therapies, leading to
striking synergism, at least in preclinical models. In this brief review, we highlight some of the more
promising strategies targeting Mcl-1 in AML, with a particular emphasis on rational combinations of
novel agents.
& 2013 Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
Multiple signal transduction pathways in normal and malig-
nant cells converge on Bcl-2 family proteins, which stand at the
crossroads between cell survival and apoptosis. The seminal event
in the intrinsic pathway of apoptosis is mitochondrial outer
membrane permeabilization (MOMP), induced by the ‘‘effector’’
Bcl-2 family proteins, Bax and Bak. The anti-apoptotic proteins
are Bcl-2, Bcl-XL, Bcl-w, Mcl-1, Bﬂ-1/A1 and Bcl-B. The ‘‘multi-
domain’’ pro-apoptotic proteins are Bax, Bak and Bok, which share
homology in domains BH (Bcl-2 homology) 1–3. The other pro-
apoptotic Bcl-2 family proteins share only the BH3 domain and
are termed ‘‘BH3-only’’ proteins; these include Bim, Bid, Bad, Bik,
Hrk, Bmf, Puma and Noxa. The BH3 domain enables binding to a
hydrophobic groove on the surface of the anti-apoptotic Bcl-2
molecules. Under normal conditions, pro-apoptotic BH3-onlycine (Hematology/Oncology),
cer Center, Shirley Carter and
College Street, Room 234,
35, USA.
-NC-ND license.proteins prevent the anti-apoptotic Bcl-2 proteins from engaging
with the apoptosis effectors Bax and Bak, allowing the latter to
trigger apoptosis upon receipt of a death signal. Alternatively,
‘‘direct activator’’ BH3-only proteins may be held in check by
their anti-apoptotic counterparts. Fig. 1 illustrates some of these
concepts.2. Mcl-1
Mcl-1 is distinguished from other anti-apoptotic Bcl-2 proteins
in that it has a very short half-life (only 2–4 h in most cells),
making it dependent upon active transcription and translation for
its maintenance. Mcl-1 sequesters, in conjunction with Bcl-XL, the
apoptotic effector Bak on the mitochondrial surface, protecting
against Bak oligomerization and the induction of MOMP. Mcl-1
also interacts with and sequesters the pro-apoptotic proteins Bim
and truncated Bid. Noxa antagonizes Mcl-1 and promotes its
proteasomal degradation, freeing Bak and Bim (Fig. 1). Because
of structural differences, Mcl-1 is not bound by ABT-737, a
potent small-molecule ‘‘BH3-mimetic’’ antagonist of Bcl-2, Bcl-XL
and Bcl-w, which thus mimics the actions of Bad (Fig. 1). Indeed,
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Navitoclax
CDK9 inhibitors
(transcription   ) MEK inhibitors
USP9X inhibitors 
(   degradation)
Obatoclax Bax
Bax
Mitochondrial
outer membrane
/ER membrane
Apoptosis 
Bak
DNA 
Bak
Bax Bax
Conformation 
Mcl-1 Bcl-xL
Bcl-2 
inactive active 
NOXA
Bad
BakBak
Sorafenib
Level 1
Level 2
ER Stress
translation
Bim
Bim
Bim
FLT3
Fig. 1. Schematic representation of interactions between pro- and anti-apoptotic members of the Bcl-2 family and various pharmacologic mechanisms of
triggering apoptosis via the intrinsic, or mitochondrial pathway. Upon activation, the apoptosis effectors Bax and Bak induce permeabilization of the mitochondrial
outer membrane, resulting in a cascade of events that trigger cell death. Under normal conditions, the anti-apoptotic proteins Bcl-2, Bcl-XL and Mcl-1 sequester apoptosis
effectors (e.g., Bak) as well as the pro-apoptotic ‘‘BH3-only’’ protein Bim, thereby preventing apoptosis. The BH3-only proteins Bad and Noxa, as well as ‘‘BH3-mimetic’’
drugs such as navitoclax and obatoclax untether the apoptosis effectors and Bim from the anti-apoptotic proteins, leading to apoptosis. In addition, a variety of
pharmacologic strategies may be used to down-regulate Mcl-1. These include inhibition of translation by sorafenib, transcriptional repression by CDK9 inhibitors such as
ﬂavopiridol (alvocidib) or roscovitine (seliciclib), MEK inhibitors, and inhibitors of deubiquitinase USP9X, which enhance its degradation. These agents have the potential
to potentiate the effects of BH3-mimetics, and vice versa. As sorafenib potently inhibits FLT3, which up-regulates Mcl-1 and Bcl-XL and phosphorylates Bad (leading to its
degradation) via several different downstream pathways (not shown), combinations involving this agent may be particularly effective in FLT3-mutated AML, as seen in
preclinical studies of sorafenib and obatoclax.
Modiﬁed from Dai Y, Grant S. Cancer Research 2007;67:2908–11 (Fig. 1). &2007. American Association for Cancer Research.
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underlying leukemia cell resistance to ABT-737.1
While up-regulation of Mcl-1 has been described at the time of
AML relapse, in fms-like tyrosine kinase-internal tandem duplica-
tion (FLT3-ITD) AML stem cells, and in the regulation of stem cell
self-renewal, the most compelling evidence to date in support
of a critical role for Mcl-1 in the survival of human AML cells
emanates from a recent study in which deletion of Mcl-1, but not
loss or pharmacological blockade of Bcl-XL, Bcl-2, or Bcl-w,
induced the death of transformed AML and cured disease in
AML-afﬂicted mice.2
2.1. Simultaneously targeting multiple arms of the apoptotic
regulatory machinery (Fig. 1)
As ABT-737 does not inhibit Mcl-1, combining such agents
with drugs capable of down-regulating Mcl-1 is a particularly
appealing therapeutic strategy in AML, analogous to Bad and
Noxa, which synergistically induce apoptosis. In this context,
cyclin dependent kinase (CDK) inhibitors that inhibit the cyclin
T-CDK9 complex (positive transcription elongation factor b,
P-TEFb), such as ﬂavopiridol (alvocidib), roscovitine (seliciclib)
or SCH727965 (dinaciclib), down-regulate Mcl-1 by acting as
transcriptional repressors. Thus, roscovitine dramatically increases
ABT-737 lethality in human leukemia cells.3 Coadministration of
roscovitine and ABT-737 untethered Bak from Mcl-1 and Bcl-XL,
respectively, triggering Bak activation and Bax translocation, with
resultant induction of MOMP.
Another mechanism of down-regulating Mcl-1 involves inhi-
bition of translation. It has been demonstrated that the multi-
targeted tyrosine kinase inhibitor sorafenib mediates apoptotic
cell death in human leukemia cells, at least in part, through
down-regulation of Mcl-1 via inhibition of translation.4 Accord-
ingly, sorafenib synergizes with ABT-737 to induce apoptosis in
AML cell lines.5ABT-737 may induce activation of extracellular signal regu-
lated kinase and up-regulation of Mcl-1 in AML cells, arguing
for a combination strategy involving inhibitors of mitogen acti-
vated protein kinase (MEK), which have been used successfully to
suppress Mcl-1. Indeed, the MEK inhibitor PD0325901 potently
synergizes with ABT-737 to promote killing of AML-derived cell
lines, primary AML blasts, and CD34þ38–123þ AML progenitor/
stem cells, both in vitro and in vivo.6
Navitoclax (ABT-263) is an orally available analog of ABT-737.
Based on the promising laboratory ﬁndings noted above, clinical
trials of navitoclax in combination with sorafenib, transcriptional
CDK inhibitors, or MEK inhibitors in patients with AML are under
consideration.
2.2. Combining down-regulation of Mcl-1 with antagonism of Mcl-1
function
Obatoclax (GX15-070) is another small-molecule BH3-mimetic
that inhibits Mcl-1 in addition to Bcl-2, Bcl-xL and Bcl-w through
a Noxa-dependent mechanism. Obatoclax potently interferes with
the sequestration of Bak by Mcl-1, untethering Bak and over-
coming resistance to apoptosis conferred by Mcl-1.7 In leukemia
cell lines and primary AML cells, obatoclax both triggers apoptosis
and induces autophagy.8 Apoptosis in this setting was preceded
by the release of Bak from Mcl-1, liberation of Bim from both
Bcl-2 and Mcl-1, and the formation of an active Bak/Bax complex.
A recent study has demonstrated marked potentiation by obato-
clax of sorafenib-induced apoptosis in multiple AML cell lines and
primary AML cells but not normal CD34þ cells.9 Indeed, exposure
to comparable or signiﬁcantly higher concentrations of sorafenib
and obatoclax alone or in combination exhibited minimal leth-
ality toward normal CD34þ cells. Up-regulation of Bcl-2 family
anti-apoptotic proteins represents an important mechanism of
therapeutic resistance to sorafenib, and can be abolished by the
concomitant administration of obatoclax. In line with the known
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lower sorafenib concentrations in FLT3-mutated cells. In FLT3-ITD
AML, up-regulation of Mcl-1 is dependent on FLT3 signaling and
an essential effector of FLT3-ITD-mediated drug resistance, and
down-regulation of Mcl-1 sensitizes FLT3-ITD hematopoietic cells
to cytotoxic and targeted therapies.10 In light of these observa-
tions, a National Cancer Institute-sponsored phase I/Ib trial
(with a limited expansion cohort in FLT3-mutated patients) of
sorafenib and obatoclax in patients with relapsed/refractory and
selected poor prognosis types of AML or MDS is planned by the
Southeast Phase II consortium. This strategy of simultaneously
down-regulating Mcl-1 with sorafenib and inhibiting its function
(and that of Bcl-2 and Bcl-XL) with obatoclax to trigger apoptosis
in AML cells is depicted schematically in Fig. 1.
2.3. Combinations of agents capable of down-regulating Mcl-1 with
cytotoxic chemotherapy
Preclinical studies have shown that in addition to triggering
apoptosis, ﬂavopiridol may recruit surviving leukemia cells to a
proliferative state, thereby priming such cells for the S-phase-
related cytotoxicity of cytarabine. Pretreatment with ﬂavopiridol
enhanced the pro-apoptotic and cytotoxic effects of cytarabine on
primary bone marrow blasts from patients with refractory acute
leukemias.11 Based on this concept, several clinical trials of timed
sequential therapy with ﬂavopiridol, cytarabine and mitoxan-
trone (FLAM) have been conducted. In a phase II study in 45
newly diagnosed patients with poor-risk AML, 67% achieved
complete remission (CR).12 Accordingly, a randomized phase II
study comparing FLAM to cytarabine and daunorubicin in newly
diagnosed patients with AML (NCT01413880) is currently ongoing.
Several groups have combined sorafenib with chemotherapy
in AML. In a phase II study, 51 adults with previously untreated
AML received sorafenib, cytarabine and idarubicin. While the
overall CR rate was 75%, it was signiﬁcantly higher (p¼0.033) in
FLT3-mutated patients (93%) than in FLT3-wild type (FLT3-WT)
patients (66%).13 While responses to the combination of sorafenib
and low dose cytarabine in unselected older patients with AML or
high risk MDS were disappointing,14 encouraging activity was
observed in both FLT3-mutated and FLT3-WT pediatric patients
with relapsed/refractory AML receiving sorafenib in combination
with clofarabine and cytarabine on a phase I trial.15 Whether
Mcl-1 down-regulation by sorafenib (or ﬂavopiridol) contributes
to the anti-leukemic actions of genotoxic agents remains to be
determined.3. Conclusion
Long known to be a key mediator of resistance to treatment in
multiple myeloma, Mcl-1 has recently emerged as a promising
and rational therapeutic target in AML. A variety of approaches
are potentially available through which Mcl-1 levels may theore-
tically be lowered, e.g., by interfering with its transcription or
translation, or by promoting its degradation with deubiquitinase
(e.g., USP9X) inhibitors. Alternatively, its function may be dis-
rupted, e.g., by agents such as obatoclax or gossypol/AT-101.
Particularly promising are combination approaches that simulta-
neously disrupt multiple cooperative pro-survival pathways
and/or activate their pro-apoptotic counterparts. The results oftranslational efforts attempting to recapitulate some of these
exciting preclinical ﬁndings in AML patients are eagerly awaited.Contributions
P.B. drafted the article. S.G. revised the article critically for
important intellectual content.Acknowledgments
This work was supported by the following awards to S.G. from
the National Institutes of Health: Nos. CA93738, CA100866,
CA148431, CA137823, CA142509, and CA130805, and an award
from the Leukemia and Lymphoma Society of America.
References
1. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al.
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-
737 in acute myeloid leukemia. Cancer Cell 2006;10:375–88.
2. Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, et al. Anti-
apoptotic Mcl-1 is essential for the development and sustained growth of
acute myeloid leukemia. Genes and Development 2012;26:120–5.
3. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates
ABT-737 lethality by cooperatively inducing Bak activation and Bax transloca-
tion. Cancer Research 2007;67:782–91.
4. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the
kinase inhibitor BAY 43-9006 in human leukemia cells involves down-
regulation of Mcl-1 through inhibition of translation. Journal of Biological
Chemistry 2005;280:35217–27.
5. Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, BornmannWG, et al.
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the
intrinsic apoptotic pathway. Leukemia 2008;22:808–18.
6. Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, et al.
MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via pre-
vention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM
complex. Leukemia 2012;26:778–87.
7. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju
SR, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and
overcomes MCL-1-mediated resistance to apoptosis. Proceedings of the
National Academy of Sciences of the United States of America 2007;104:19512–7.
8. Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, et al. Mechan-
isms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic
GX15-070 (obatoclax). Cancer Research 2008;68:3413–20.
9. Rahmani M, Aust MM, Attkisson E, Williams Jr. DC, Ferreira-Gonzalez A, Grant
S. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances
sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-
dependent process. Blood 2012;119:6089–98.
10. Kasper S, Breitenbuecher F, Heidel F, Hoffarth S, Markova B, Schuler M, et al.
Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic thera-
pies. Blood Cancer Journal 2012;2:e60.
11. Karp JE, Ross DD, Yang W, Tidwell ML, Wei Y, Greer J, et al. Timed Sequential
Therapy of Acute Leukemia with Flavopiridol. Clinical Cancer Research
2003;9:307–15.
12. Karp JE, Blackford A, Smith BD, Alino K, Seung AH, Bolanos-Meade J, et al.
Clinical activity of sequential ﬂavopiridol, cytosine arabinoside, and mitoxan-
trone for adults with newly diagnosed, poor-risk acute myelogenous leuke-
mia. Leukemia Research 2010;34:877–82.
13. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, et al.
Phase I/II study of combination therapy with sorafenib, idarubicin, and
cytarabine in younger patients with acute myeloid leukemia. Journal of Clinical
Oncology 2010;28:1856–62.
14. Macdonald DA, Assouline SE, Brandwein J, Kamel-Reid S, Eisenhauer EA,
Couban S, et al. Phase I/II study of sorafenib (Bay 43-9006) in combination
with low dose cytarabine (LDAC) in elderly patients with AML or high-risk
MDS from The NCIC Clinical Trials Group: Trial IND.186. Leukemia and
Lymphoma 2012, Nov. 15 [Epub ahead of print].
15. Inaba H, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP, et al.
Phase I pharmacokinetic and pharmacodynamic study of the mssultikinase
inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric
relapsed/refractory leukemia. Journal of Clinical Oncology 2011;29:3293–300.
